Download PDF
Int J Angiol 2023; 32(03): 165-171
DOI: 10.1055/s-0042-1756488
Original Article

Could Plasma CXCL12 Predict Ventricular Dysfunction in Patients with Severe Myocardial Infarction?

Hussam A. S. Murad 
1   Department of Pharmacology, Faculty of Medicine in Rabigh, King Abdulaziz University, Jeddah, Saudi Arabia
,
Marwan A. Bakarman
2   Department of Family and Community Medicine, Faculty of Medicine in Rabigh, King Abdulaziz University, Jeddah, Saudi Arabia
› Author Affiliations
› Further Information
    Permissions and Reprints

Abstract

Plasma level of chemokine CXCL12 can predict adverse cardiovascular outcomes in patients with coronary artery disease, but data on its relationship with severity of coronary stenosis in cases of severe myocardial infarction (MI) are scarce and conflicting. The objective of this study was to investigate link between plasma CXCL12 levels and different grades of left ventricular ejection fraction (LVEF) in statin-treated and -untreated patients with severe MI. A total of 198 consecutive patients with first-time severe MI (ST-elevated myocardial infarction [STEMI], n = 121 and non-ST-elevated myocardial infarction [NSTEMI], n = 77) were recruited from Coronary Care Unit, King Abdulaziz University Hospital. They have one to two coronary arteries blocked ≥50%, or three arteries blocked 30 to 49%. Demographic and clinical criteria were collected and plasma CXCL12 level was measured. No correlations were detected between demographic and clinical criteria and CXCL12 level. While troponin peaks and LVEF significantly differed between STEMI and NSTEMI patients, CXCL12 level showed nonsignificant changes. Plasma CXCL12 levels decreased significantly in statin-treated patients compared with those untreated. From receiver operating characteristic (ROC) analysis, high CXCL12 levels were associated with no statin therapy. For STEMI and NSTEMI patients, area under the receiver operating characteristic curve for CXCL12 test were 0.685 and 0.820, while sensitivity and specificity values were 75.9 and 54.8%, and 73.1 and 84%, respectively. Plasma CXCL12 levels showed nonsignificant changes with different ranges of LVEF and troponin peaks. In patients with severe MI, irrespective of statin therapy, plasma CXCL12 showed no correlation with different ranges of LVEF suggesting that it cannot predict left ventricular dysfunction in these cases. However, cross-sectional design of this study is a limitation.

Keywords

plasma CXCL12 - left ventricular ejection fraction - acute coronary syndrome - statin


Publication History

Article published online:
23 September 2022

© 2022. International College of Angiology. This article is published by Thieme.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Daga LC, Kaul U, Mansoor A. Approach to STEMI and NSTEMI. J Assoc Physicians India 2011; 59 (Suppl): 19-25
    PubMedGoogle Scholar
  • 2 Karin N. The multiple faces of CXCL12 (SDF-1alpha) in the regulation of immunity during health and disease. J Leukoc Biol 2010; 88 (03) 463-473
    CrossrefPubMedGoogle Scholar
  • 3 Huang Y, Zhou J, Ye H. et al. Relationship between chemokine (C-X-C motif) ligand 12 gene variant (rs1746048) and coronary heart disease: case-control study and meta-analysis. Gene 2013; 521 (01) 38-44
    CrossrefPubMedGoogle Scholar
  • 4 Keeley EC, Moorman JR, Liu L. et al. Plasma chemokine levels are associated with the presence and extent of angiographic coronary collaterals in chronic ischemic heart disease. PLoS One 2011; 6 (06) e21174
    CrossrefPubMedGoogle Scholar
  • 5 Miller JM, Rochitte CE, Dewey M. et al. Diagnostic performance of coronary angiography by 64-row CT. N Engl J Med 2008; 359 (22) 2324-2336
    CrossrefPubMedGoogle Scholar
  • 6 Chen J, Chemaly E, Liang L. et al. Effects of CXCR4 gene transfer on cardiac function after ischemia-reperfusion injury. Am J Pathol 2010; 176 (04) 1705-1715
    CrossrefPubMedGoogle Scholar
  • 7 Hao H, Hu S, Chen H. et al. Loss of endothelial CXCR7 impairs vascular homeostasis and cardiac remodeling after myocardial infarction: implications for cardiovascular drug discovery. Circulation 2017; 135 (13) 1253-1264
    CrossrefPubMedGoogle Scholar
  • 8 Murad HAS, Rafeeq MM, Alqurashi TMA. Role and implications of the CXCL12/CXCR4/CXCR7 axis in atherosclerosis: still a debate. Ann Med 2021; 53 (01) 1598-1612
    CrossrefPubMedGoogle Scholar
  • 9 Rath D, Schaeffeler E, Winter S. et al. SDF1 polymorphisms influence outcome in patients with symptomatic cardiovascular disease. PLoS One 2016; 11 (09) e0161933
    CrossrefPubMedGoogle Scholar
  • 10 Mehta NN, Li M, William D. et al. The novel atherosclerosis locus at 10q11 regulates plasma CXCL12 levels. Eur Heart J 2011; 32 (08) 963-971
    CrossrefPubMedGoogle Scholar
  • 11 Stellos K, Langer H, Daub K. et al. Platelet-derived stromal cell-derived factor-1 regulates adhesion and promotes differentiation of human CD34+ cells to endothelial progenitor cells. Circulation 2008; 117 (02) 206-215
    CrossrefPubMedGoogle Scholar
  • 12 Elmadbouh I, Haider HKh, Jiang S, Idris NM, Lu G, Ashraf M. Ex vivo delivered stromal cell-derived factor-1alpha promotes stem cell homing and induces angiomyogenesis in the infarcted myocardium. J Mol Cell Cardiol 2007; 42 (04) 792-803
    CrossrefPubMedGoogle Scholar
  • 13 Teicher BA, Fricker SP. CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res 2010; 16 (11) 2927-2931
    CrossrefPubMedGoogle Scholar
  • 14 Décaillot FM, Kazmi MA, Lin Y, Ray-Saha S, Sakmar TP, Sachdev P. CXCR7/CXCR4 heterodimer constitutively recruits β-arrestin to enhance cell migration. J Biol Chem 2011; 286 (37) 32188-32197
    CrossrefPubMedGoogle Scholar
  • 15 Tang CH, Tan TW, Fu WM, Yang RS. Involvement of matrix metalloproteinase-9 in stromal cell-derived factor-1/CXCR4 pathway of lung cancer metastasis. Carcinogenesis 2008; 29 (01) 35-43
    CrossrefPubMedGoogle Scholar
  • 16 Klasen C, Ohl K, Sternkopf M. et al. MIF promotes B cell chemotaxis through the receptors CXCR4 and CD74 and ZAP-70 signaling. J Immunol 2014; 192 (11) 5273-5284
    CrossrefPubMedGoogle Scholar
  • 17 Timotijević G, Mostarica Stojković M, Miljković D. CXCL12: role in neuroinflammation. Int J Biochem Cell Biol 2012; 44 (06) 838-841
    CrossrefPubMedGoogle Scholar
  • 18 Liu KK, Dorovini-Zis K. Regulation of CXCL12 and CXCR4 expression by human brain endothelial cells and their role in CD4+ and CD8+ T cell adhesion and transendothelial migration. J Neuroimmunol 2009; 215 (1-2): 49-64
    CrossrefPubMedGoogle Scholar
  • 19 Jiangping S, Zhe Z, Wei W. et al. Assessment of coronary artery stenosis by coronary angiography: a head-to-head comparison with pathological coronary artery anatomy. Circ Cardiovasc Interv 2013; 6 (03) 262-268
    CrossrefPubMedGoogle Scholar
  • 20 Chatterjee M. Atypical roles of the chemokine receptor ACKR3/CXCR7 in platelet pathophysiology. Cells 2022; 11 (02) 213
    CrossrefPubMedGoogle Scholar
  • 21 Mukherjee JT, Beshansky JR, Ruthazer R. et al. In-hospital measurement of left ventricular ejection fraction and one-year outcomes in acute coronary syndromes: results from the IMMEDIATE Trial. Cardiovasc Ultrasound 2016; 14 (01) 29
    CrossrefPubMedGoogle Scholar
  • 22 Mahajan VS, Jarolim P. How to interpret elevated cardiac troponin levels. Circulation 2011; 124 (21) 2350-2354
    CrossrefPubMedGoogle Scholar
  • 23 Apple FS, Ler R, Murakami MM. Determination of 19 cardiac troponin I and T assay 99th percentile values from a common presumably healthy population. Clin Chem 2012; 58 (11) 1574-1581
    CrossrefPubMedGoogle Scholar
  • 24 Garg P, Morris P, Fazlanie AL. et al. Cardiac biomarkers of acute coronary syndrome: from history to high-sensitivity cardiac troponin. Intern Emerg Med 2017; 12 (02) 147-155
    CrossrefPubMedGoogle Scholar
  • 25 Ghasemzadeh N, Hritani AW, De Staercke C. et al. Plasma stromal cell-derived factor 1α/CXCL12 level predicts long-term adverse cardiovascular outcomes in patients with coronary artery disease. Atherosclerosis 2015; 238 (01) 113-118
    CrossrefPubMedGoogle Scholar
  • 26 Tavakolian Ferdousie V, Mohammadi M, Hassanshahi G. et al. Serum CXCL10 and CXCL12 chemokine levels are associated with the severity of coronary artery disease and coronary artery occlusion. Int J Cardiol 2017; 233: 23-28
    CrossrefPubMedGoogle Scholar
  • 27 Wyderka R, Wojakowski W, Jadczyk T. et al. Mobilization of CD34+CXCR4+ stem/progenitor cells and the parameters of left ventricular function and remodeling in 1-year follow-up of patients with acute myocardial infarction. Mediators Inflamm 2012; 2012: 564027
    CrossrefPubMedGoogle Scholar
  • 28 Ostadal P. Statins as first-line therapy for acute coronary syndrome?. Exp Clin Cardiol 2012; 17 (04) 227-236
    PubMedGoogle Scholar
  • 29 Chou R, Dana T, Blazina I. et al. Statin use for the prevention of cardiovascular disease in adults: a systematic review for the US Preventive Services Task Force. RE:view 2016; x: x
    PubMedGoogle Scholar
  • 30 Camnitz W, Burdick MD, Strieter RM, Mehrad B, Keeley EC. Dose-dependent effect of statin therapy on circulating CXCL12 levels in patients with hyperlipidemia. Clin Transl Med 2012; 1 (01) 23
    CrossrefPubMedGoogle Scholar
  • 31 Yancy CW, Jessup M, Bozkurt B. et al; American College of Cardiology Foundation, American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; 62 (16) e147-e239
    PubMedGoogle Scholar
  • 32 Scanlon PJ, Faxon DP, Audet AM. et al. ACC/AHA guidelines for coronary angiography: executive summary and recommendations. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Coronary Angiography) developed in collaboration with the Society for Cardiac Angiography and Interventions. Circulation 1999; 99 (17) 2345-2357
    CrossrefPubMedGoogle Scholar
  • 33 Johns Hopkins Medicine. Updated Classification System Captures Many More People at Risk for Heart Attack. 2017. Accessed March 6, 2022, at: https://www.hopkinsmedicine.org/news/media/releases/updated_classification_system_captures_many_more_people_at_risk_for_heart_attack
    PubMedGoogle Scholar
  • 34 Arnold SV, Spertus JA, Tang F. et al. Statin use in outpatients with obstructive coronary artery disease. Circulation 2011; 124 (22) 2405-2410
    CrossrefPubMedGoogle Scholar
  • 35 Bodí V, Núñez J, Sanchis J, Llàcer A, Fácila L, Chorro FJ. [Usefulness of troponin I for predicting systolic dysfunction in acute coronary syndromes. Results of a prospective and quantitative study]. Rev Esp Cardiol 2003; 56 (07) 738-741
    PubMedGoogle Scholar
  • 36 Cummins B, Auckland ML, Cummins P. Cardiac-specific troponin-I radioimmunoassay in the diagnosis of acute myocardial infarction. Am Heart J 1987; 113 (06) 1333-1344
    CrossrefPubMedGoogle Scholar
  • 37 Cleveland Clinic. Ejection Fraction. 2019. Accessed 6 March, 2022, at: https://my.clevelandclinic.org/health/articles/16950-ejection-fraction
    PubMedGoogle Scholar
  • 38 Cannon CP, Braunwald E, McCabe CH. et al; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350 (15) 1495-1504
    CrossrefPubMedGoogle Scholar
  • 39 Kim C, Choi D. Timing of high intensity statin for acute coronary syndrome: how earlier initiation makes better?. J Thorac Dis 2018; 10 (Suppl. 18) S2149-S2152
    CrossrefPubMedGoogle Scholar
  • 40 Yu S, Jin J, Chen Z, Luo X. High-intensity statin therapy yields better outcomes in acute coronary syndrome patients: a meta-analysis involving 26,497 patients. Lipids Health Dis 2020; 19 (01) 194
    CrossrefPubMedGoogle Scholar